tiprankstipranks
Trending News
More News >

BioXcel Granted Nasdaq Compliance Extension Until September

Story Highlights
  • BioXcel Therapeutics received an extension from Nasdaq to regain compliance by September 16, 2025.
  • The company must achieve a market value of $35 million for 10 consecutive days to maintain its Nasdaq listing.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
BioXcel Granted Nasdaq Compliance Extension Until September

Don’t Miss TipRanks’ Half-Year Sale

Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.

On May 27, 2025, BioXcel Therapeutics announced that it received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq Listing Rule 5550(b)(2) until September 16, 2025. This extension allows the company additional time to meet the requirement of maintaining a market value of listed securities of at least $35 million for 10 consecutive business days, which is crucial for its continued listing on the Nasdaq Stock Market.

The most recent analyst rating on (BTAI) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.

Spark’s Take on BTAI Stock

According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.

Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.

To see Spark’s full report on BTAI stock, click here.

More about Bioxcel Therapeutics

BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines for neurological and immuno-oncology disorders.

Average Trading Volume: 4,666,190

Technical Sentiment Signal: Sell

Current Market Cap: $8.42M

See more insights into BTAI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1